Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:ChemotherapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Feb 2008

Description:

Patients: This study involved 40 patients with stage IV non-small cell lung cancer. There were similar numbers of women (21) and men (19). Their median age was 70, ranging from 43-84 years of age.

Treatment: Patients were treated with albumin-bound paclitaxel. This form of paclitaxel dissolves easier and is less likely to cause the immune system to overreact to it, thus reducing the need for antihistamine and corticosteroid treatments.

Toxicity: The most common grade 3 toxicity was neutropenia, leukopenia, sensory neuropathy, fatigue, and diarrhea. Grade 4 neutropenia was reported in 5% of patients.

Result: The median overall survival was 11 months.

Support: This research was supported by Abraxis BioScience, which markets this form of paclitaxel as ABRAXANE®.

Correspondence: Dr. Naiyer A. Rizvi



Back